Esperion Therapeutics ESPR Stock
Esperion Therapeutics Price Chart
Esperion Therapeutics ESPR Financial and Trading Overview
| Esperion Therapeutics stock price | 3.14 USD |
| Previous Close | 3.13 USD |
| Open | 3.13 USD |
| Bid | 2.26 USD x 200 |
| Ask | 4.01 USD x 200 |
| Day's Range | 3.13 - 3.14 USD |
| 52 Week Range | 0.85 - 4.18 USD |
| Volume | 18.58M USD |
| Avg. Volume | 11.32M USD |
| Market Cap | 805.76M USD |
| Beta (5Y Monthly) | 0.908 |
| PE Ratio (TTM) | |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.19 USD |
ESPR Valuation Measures
| Enterprise Value | 1.19B USD |
| Trailing P/E | |
| Forward P/E | 10.719178 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.9265357 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 2.853 |
| Enterprise Value/EBITDA | 15.725 |
Trading Information
Esperion Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.908 |
| 52-Week Change | 240.21% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 4.18 USD |
| 52 Week Low | 0.85 USD |
| 50-Day Moving Average | 2.63 USD |
| 200-Day Moving Average | 2.95 USD |
ESPR Share Statistics
| Avg. Volume (3 month) | 11.32M USD |
| Avg. Daily Volume (10-Days) | 7.12M USD |
| Shares Outstanding | 257.43M |
| Float | 255.18M |
| Short Ratio | 1.02 |
| % Held by Insiders | 0.68% |
| % Held by Institutions | 69.77% |
| Shares Short | 20.21M |
| Short % of Float | 7.96% |
| Short % of Shares Outstanding | 7.84% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -1.77% |
| Operating Margin (ttm) | -8.21% |
| Gross Margin | 57.78% |
| EBITDA Margin | 18.14% |
Management Effectiveness
| Return on Assets (ttm) | 12.04% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 418.24M USD |
| Revenue Per Share (ttm) | 1.89 USD |
| Quarterly Revenue Growth (yoy) | 23.20% |
| Gross Profit (ttm) | 241.7M USD |
| EBITDA | 75.89M USD |
| Net Income Avi to Common (ttm) | -7423000 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 156.16M USD |
| Total Cash Per Share (mrq) | 0.61 USD |
| Total Debt (mrq) | 543.81M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.53 |
| Book Value Per Share (mrq) | -1.231 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18187000 USD |
| Levered Free Cash Flow (ttm) | -49706376 USD |
Profile of Esperion Therapeutics
| Country | United States |
| State | MI |
| City | Ann Arbor |
| Address | 3891 Ranchero Drive |
| ZIP | 48108 |
| Phone | 734 887 3903 |
| Website | https://www.esperion.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 294 |
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Q&A For Esperion Therapeutics Stock
What is a current ESPR stock price?
Esperion Therapeutics ESPR stock price today per share is 3.14 USD.
How to purchase Esperion Therapeutics stock?
You can buy ESPR shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Esperion Therapeutics?
The stock symbol or ticker of Esperion Therapeutics is ESPR.
Which industry does the Esperion Therapeutics company belong to?
The Esperion Therapeutics industry is Drug Manufacturers - Specialty & Generic.
How many shares does Esperion Therapeutics have in circulation?
The max supply of Esperion Therapeutics shares is 257.43M.
What is Esperion Therapeutics Price to Earnings Ratio (PE Ratio)?
Esperion Therapeutics PE Ratio is now.
What was Esperion Therapeutics earnings per share over the trailing 12 months (TTM)?
Esperion Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Esperion Therapeutics company belong to?
The Esperion Therapeutics sector is Healthcare.
Esperion Therapeutics ESPR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Biotechnology Total Retu XNBI | 6334.93 USD — |
+1.87
|
— — | 6201.97 USD — | 6337.77 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}